+44 7868 792050
Introduction: In this study the effect of fexofenadine as an adjunct to diphenylcyclopropenone (DPCP) in non-atopic patients with Alopecia areata (AA) is investigated.
Patients and methods: Prospectively 100 patients with AA having hair loss of more than 25% of the scalp are randomly divided into two groups in group A patients received topical DPCP plus oral fexofenafine, in group B patients received only topical DPCP.
Results: Regrowth in group A was better than group B but this was not statistically significant. Eczematous reaction and pruritus was significantly lower in group A than in group B.
Discussion: Fexofenadine seems to be of no benefit in patients without underlying contributing situation. Therefore, it can be added to conventional regimen in order to enhance the compliance of patients by reducing discomfort of DPCP treatment.